<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="95901">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02078856</url>
  </required_header>
  <id_info>
    <org_study_id>A3384-001</org_study_id>
    <nct_id>NCT02078856</nct_id>
  </id_info>
  <brief_title>Double-blind, Randomised Study of A3384 in BAM/BAD</brief_title>
  <official_title>A Phase II, Placebo-controlled, Multi-centre, Dose-finding Efficacy and Safety Study of a Range of Doses of A3384 in Patients With Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Albireo</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Albireo</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to determine the efficacy and safety of A3384 administered to
      patients with Bile Acid Malabsorption (BAM)/Bile Acid Diarrhoea (BAD).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Anticipated">December 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The primary efficacy objective of this study is to demonstrate the efficacy of different daily doses of A3384 as determined by the # of bowel movements (BMs).</measure>
    <time_frame>2 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Secondary efficacy objectives of this study are to demonstrate the efficacy of different daily doses on other BM parameters and BAM/BAD symptoms</measure>
    <time_frame>Baseline and 2 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change from Baseline in average severity of diarrhoea during the second treatment week (last 7 days of reporting).
Change from Baseline in average severity of abdominal discomfort during the second treatment week (last 7 days of reporting).
Change from Baseline in average severity of abdominal bloating during the second treatment week (last 7 days of reporting).
Change from Baseline in average BSFS during the second treatment week (last 7 days of reporting)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Bile Acid Malabsorption</condition>
  <arm_group>
    <arm_group_label>A3384 Low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily for the duration of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A3384 High dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administered twice daily for the duration of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Administered twice daily for the duration of the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A3384</intervention_name>
    <arm_group_label>A3384 Low dose</arm_group_label>
    <arm_group_label>A3384 High dose</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient meets protocol specified criteria for Bile Acid Malabsorption/Bile Acid
             Diarrhoea

          -  Patient has successfully completed study requirements with no clinically relevant
             findings for physical exam, ECG, laboratory tests as applicable

        Exclusion Criteria:

          -  Medical history or medical condition that would not make the patient a good candidate
             for the study or limit the patientÂ´s ability to complete the study

          -  Patient needs medications prohibited as specified in the protocol
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hans Graffner, MD</last_name>
    <email>hans.graffner@albireopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hammersmith Hospital, Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <zip>W12 0HS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Appleby, MD</last_name>
      <email>r.appleby@imperial.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Julian R Walters, MBBS MA FRCP</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 4, 2014</lastchanged_date>
  <firstreceived_date>March 3, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Malabsorption Syndromes</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
